NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.

FOXM1 NPM-ALK anaplastic large cell lymphoma gene regulation thiostrepton

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
06 Aug 2019
Historique:
received: 11 06 2019
revised: 23 07 2019
accepted: 29 07 2019
entrez: 9 8 2019
pubmed: 9 8 2019
medline: 9 8 2019
Statut: epublish

Résumé

Forkhead Box M1 (FOXM1) is an oncogenic transcription factor implicated in the pathogenesis of solid and hematologic cancers. In this study, we examined the significance of FOXM1 in NPM-ALK-positive anaplastic large cell lymphoma (NPM-ALK + ALCL), with a focus on how it interacts with NPM-ALK, which is a key oncogenic driver in these tumors. FOXM1 was expressed in NPM-ALK + ALCL cell lines (5/5), patient samples (21/21), and tumors arising in NPM-ALK transgenic mice (4/4). FOXM1 was localized in the nuclei and confirmed to be transcriptionally active. Inhibition of FOXM1 in two NPM-ALK + ALCL cells using shRNA and pharmalogic agent (thiostrepton) resulted in reductions in cell growth and soft-agar colony formation, which were associated with apoptosis and cell-cycle arrest. FOXM1 is functionally linked to NPM-ALK, as FOXM1 enhanced phosphorylation of the NPM-ALK/STAT3 axis. Conversely, DNA binding and transcriptional activity of FOXM1 was dependent on the expression of NPM-ALK. Further studies showed that this dependency hinges on the binding of FOXM1 to NPM1 that heterodimerizes with NPM-ALK, and the phosphorylation status of NPM-ALK. In conclusion, we identified FOXM1 as an important oncogenic protein in NPM-ALK+ ALCL. Our results exemplified that NPM-ALK exerts oncogenic effects in the nuclei and illustrated a novel role of NPM1 in NPM-ALK pathobiology.

Identifiants

pubmed: 31390744
pii: cancers11081119
doi: 10.3390/cancers11081119
pmc: PMC6721812
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer Res. 2001 Mar 1;61(5):2194-9
pubmed: 11280786
FEBS Lett. 2001 Oct 19;507(1):59-66
pubmed: 11682060
Oncogene. 2002 Feb 7;21(7):1038-47
pubmed: 11850821
J Cell Sci. 2005 Feb 15;118(Pt 4):795-806
pubmed: 15671063
Methods Mol Biol. 2006;338:281-90
pubmed: 16888365
Oncogene. 2007 Feb 8;26(6):813-21
pubmed: 16909118
Blood. 2007 Oct 1;110(7):2259-67
pubmed: 17519389
Nat Rev Cancer. 2007 Nov;7(11):847-59
pubmed: 17943136
J Biol Chem. 2008 Jul 25;283(30):20770-8
pubmed: 18524773
Blood. 2008 Dec 15;112(13):5171-9
pubmed: 18787224
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18794-9
pubmed: 19033198
Methods Mol Biol. 2009;506:83-96
pubmed: 19110621
Haematologica. 2009 Jul;94(7):897-900
pubmed: 19570751
Cell Cycle. 2009 Oct 15;8(20):3425-7
pubmed: 19806025
Breast Cancer Res Treat. 2010 Jul;122(2):337-46
pubmed: 19813088
PLoS One. 2010 Feb 16;5(2):e9229
pubmed: 20169079
Nucleic Acids Res. 2010 Dec;38(22):8027-38
pubmed: 20702419
Carcinogenesis. 2011 Feb;32(2):146-53
pubmed: 21045017
Nat Chem. 2011 Aug 21;3(9):725-31
pubmed: 21860463
Biochim Biophys Acta. 2012 Jan;1819(1):28-37
pubmed: 21978825
J Biol Chem. 2011 Dec 2;286(48):41425-33
pubmed: 21979956
Cancer Cell. 2011 Oct 18;20(4):427-42
pubmed: 22014570
Haematologica. 2012 Jul;97(7):1092-100
pubmed: 22271891
Blood Cancer J. 2012 Aug 10;2:e82
pubmed: 22885405
Mol Cell Biol. 2013 Jan;33(2):227-36
pubmed: 23109430
Front Oncol. 2012 Dec 19;2:192
pubmed: 23267434
Mol Cancer Ther. 2013 May;12(5):759-67
pubmed: 23427295
Adv Cancer Res. 2013;118:97-398
pubmed: 23768511
J Vis Exp. 2014 Oct 27;(92):e51998
pubmed: 25408172
Leuk Res. 2015 Mar;39(3):342-7
pubmed: 25557384
Nat Commun. 2015 Mar 10;6:6471
pubmed: 25753524
Mol Med Rep. 2015 Jul;12(1):1457-64
pubmed: 25760224
Cancer Res. 2015 Jun 1;75(11):2337-48
pubmed: 25832656
Blood. 2015 Jul 16;126(3):336-45
pubmed: 25921060
Oncotarget. 2015 Sep 29;6(29):27613-27
pubmed: 26243836
Leukemia. 2016 Apr;30(4):873-82
pubmed: 26648534
Oncogene. 2016 Jul 21;35(29):3854-3865
pubmed: 26657151
Nat Commun. 2016 Jan 12;7:10087
pubmed: 26753883
BMC Mol Biol. 2016 Aug 24;17(1):19
pubmed: 27553022
Blood. 2017 Feb 16;129(7):823-831
pubmed: 27879258
Nucleic Acids Res. 2017 Apr 20;45(7):3707-3723
pubmed: 28003476
Leukemia. 2017 Apr;31(4):798-807
pubmed: 28111462
Cancers (Basel). 2017 Sep 05;9(9):null
pubmed: 28872581
JCI Insight. 2018 Aug 9;3(15):null
pubmed: 30089730
Cancers (Basel). 2019 Feb 21;11(2):null
pubmed: 30795624
Nucleic Acids Res. 1997 May 1;25(9):1715-9
pubmed: 9108152
Am J Pathol. 1998 Sep;153(3):875-86
pubmed: 9736036

Auteurs

Moinul Haque (M)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G2R3, Canada.

Jing Li (J)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G2R3, Canada.
Electron Microscopy Center, Basic Medical Science College, Harbin Medical University, Harbin 150080, Heilongjiang, China.

Yung-Hsing Huang (YH)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G2R3, Canada.

Meaad Almowaled (M)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G2R3, Canada.

Carter J Barger (CJ)

Eppley Institute and Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Adam R Karpf (AR)

Eppley Institute and Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Peng Wang (P)

Department of Hematology, University of Alberta, Edmonton, AB T6G2R3, Canada.

Will Chen (W)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G2R3, Canada.

Suzanne D Turner (SD)

Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK.

Raymond Lai (R)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G2R3, Canada. rlai@ualberta.ca.
Department of Oncology, University of Alberta, Edmonton, AB T6G2R3, Canada. rlai@ualberta.ca.

Classifications MeSH